Ipratropium Bromide And Albuterol Sulfate Solution
Product Images NDC 71205-051

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ipratropium Bromide And Albuterol Sulfate (NDC 71205-051). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

B5387e98-figure-01 (B5387e98 Figure 01)

Chemical structure diagram of the active ingredient, Albuterol Sulfate, as part of the combination product Ipratropium Bromide and Albuterol Sulfate inhalation solution by Proficient Rx LP.*

FDA Label Image

B5387e98-figure-02 (B5387e98 Figure 02)

Chemical structure diagram of Ipratropium Bromide showing its molecular arrangement, including a bicyclic ring, a nitrogen atom with methyl groups, and a phenyl group attached via an ester linkage, along with the bromide hydrate notation (Br•H2O).*

FDA Label Image

B5387e98-figure-03 (B5387e98 Figure 03)

A line graph showing respiratory volume in liters over hours after dosing for Albuterol, Ipratropium, and their combination as Ipratropium Bromide and Albuterol Sulfate Inhalation Solution. The graph compares different inhalation treatments across a time span of about 8 hours.*

FDA Label Image

B5387e98-figure-04 (B5387e98 Figure 04)

A table summarizing adverse events occurring in more than 1% of patients in treatment groups with Albuterol, Ipratropium, and a combination of Ipratropium Bromide and Albuterol Sulfate. It lists the number and percentage of patients experiencing various side effects by body system, including body as a whole, digestive, musculo-skeletal, respiratory, and urogenital categories, highlighting the highest percentages in the combination treatment group.*

FDA Label Image

B5387e98-figure-05 (B5387e98 Figure 05)

An instructional illustration showing the preparation of a respiratory inhalation solution. It depicts the insertion of a vial labeled with Ipratropium Bromide and Albuterol Sulfate into a dosing device or nebulizer, highlighting the process of assembling the medication for inhalation use.*

FDA Label Image

B5387e98-figure-06 (B5387e98 Figure 06)

An instructional diagram depicting the assembly or connection of a respiratory inhalation device. It shows a hand holding a component and aligning it to attach to another part of the inhaler system, illustrating proper usage or setup for delivering the inhalation solution.*

FDA Label Image

B5387e98-figure-07 (B5387e98 Figure 07)

Illustration showing the proper use of a respiratory inhalation solution device with a mouthpiece. The image depicts a person placing the mouthpiece in their mouth while holding the inhalation device, demonstrating the inhalation technique for Ipratropium Bromide and Albuterol Sulfate solution.*

FDA Label Image

B5387e98-figure-08 (B5387e98 Figure 08)

An instructional illustration showing a person using an inhalation device with a mouthpiece. The figure demonstrates the proper method to inhale the medication by placing the mouth over the device and activating it for respiratory delivery.*

FDA Label Image

71205-051-30 (B5387e98 Figure 09)

Label for Ipratropium Bromide and Albuterol Sulfate 0.5 mg / 3 mg per 3 mL inhalation solution, presented in a 15 mL container comprising 5 vials of 3 mL each. The product is relabeled by Proficient Rx LP, intended for oral inhalation use, and manufactured by Nephron Pharmaceuticals Corporation. The label includes dosage strength, package size, and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.